The FDA has granted fast track status to 67Cu-SAR-bisPSMA for metastatic prostate cancer that is resistant to hormone therapy ...
GlobalData on MSN7d
Pfizer’s Talzenna gains 14-months OS lead over mCRPC SoCResults from the company’s Talapro-2 trial saw a 38% reduction in the risk of death among HRR-mutated patients.
Patients with HRR-deficient metastatic castration-resistant prostate cancer experienced a 14-month gain in OS and a 38% lower ...
Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...
The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic ...
Greater survival rates are achieved when lutetium-177 [177 Lu] PSMA-617 is used rather than cabazitaxel in men with metastatic castration-resistant prostate cancer (mCRPC), real-world data confirm.
HealthDay on MSN2d
Talazoparib + Enzalutamide Tied to Improved Overall Survival in Metastatic Prostate CancerFor patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...
Pfizer's TALAPRO-2 study shows Talzenna + Xtandi significantly improves survival in mCRPC patients, with up to a 14-month OS ...
Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be ...
For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...
Adding talazoparib to first-line treatment with enzalutamide can improve overall survival in patients with mCRPC, phase 3 data suggest.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback